
KYTHERA Biopharmaceuticals, Inc. is a biopharmaceutical company focused on the discovery, development and commercialization of novel prescription products for the aesthetic medicine market. KYTHERA’s lead product, KYBELLA™, is the first and only approved non-surgical treatment for contouring moderate to severe submental fullness, commonly referred to as double chin. When injected into subcutaneous fat, KYBELLA™ causes the destruction of fat cells. Once destroyed, those cells cannot store or accumulate fat. KYTHERA also licensed the worldwide rights to setipiprant (KYTH-105), an early-stage potential treatment for hair loss.
Graduated in 2012
KYTHERA Biopharmaceuticals was acquired by Allergan for approximately $2.1 billion in 2015.
Contact:Graduated in 2012
KYTHERA Biopharmaceuticals was acquired by Allergan for approximately $2.1 billion in 2015.
www.allergan.com/contact
Graduated Companies
- Adaptix
- Aneeve
- Aneuvo
- Appia Bio
- Bluefin Foods
- Carbonics
- Charlot Biosciences
- CBD Research Institute
- Cellmic
- Concrete-AI
- Craytex
- CytoLumina
- DARTS Sciences
- Electronucleics
- EP Dynamics
- Ferrologix
- Horizon PV
- Inspira
- Inston
- InvVax
- Kelvi
- Keyssa
- Kythera Biopharmaceuticals
- Librede
- Lucendi
- Matrix Sensors, Inc.
- MAX BioPharma
- MediSens Wireless
- MicrobeDx
- Millibatt
- MyoGene Bio
- Myst Therapeutics
- NanoClear
- NanoH₂O
- Nanopixel Technologies
- National Institute of Cannabinoid Research (NICR)
- Octant
- Omega Biosystems
- Orchard Therapeutics
- Polyradiant
- Qwixel Therapeutics
- Sardona Therapeutics
- SELFA
- Sixal
- Spectradyne Particle Analysis
- Tempo Therapeutics
- TrueCath
- U-Defi
- Valerion Therapeutics
- Vivibaba
- Zenomics
- Back to Portfolio